论文部分内容阅读
目的:探讨荧光原位杂交技术(FISH)检测乳腺癌Her-2/neu的扩增情况,比较FISH法与免疫组织化学(I HC)法检测结果的一致性。方法:收集乳腺癌患者手术切除的肿瘤标本50例。经石蜡包埋,组织切片后,应用FISH法检测Her-2/neu扩增情况,I HC法检测Her-2/neu蛋白表达情况,并对两种检测方法的结果进行统计学分析。结果:50例标本中FISH阳性17例,FISH阴性33例,FISH阳性率34%(17/50)。50例标本中I HC(～)14例,I HC(0～+)36例,I HC蛋白表达率28%(14/50)。FISH法与I HC法检测结果的总符合率为82%(41/50)(K=0.581)。结论:FISH法具有较高的稳定性与可靠性,临床开展FISH法检测Her-2/neu基因扩增情况作为I HC法的补充,可以更加准确和客观地对乳腺癌患者的治疗和预后进行评价。
Objective: To investigate the amplification of Her-2 / neu in breast cancer detected by fluorescence in situ hybridization (FISH) and to compare the consistency between FISH and immunohistochemistry (I HC). Methods: Fifty patients with surgically resected breast cancer were collected. After paraffin-embedding and tissue sectioning, the amplification of Her-2 / neu was detected by FISH, the expression of Her-2 / neu was detected by I HC, and the results of two methods were statistically analyzed. Results: Of the 50 specimens, 17 were positive for FISH, 33 were negative for FISH, and the positive rate of FISH was 34% (17/50). Among the 50 specimens, 14 cases of I HC (~), 36 cases of I HC (0 ~ +), and 28% (14/50) of I HC protein expression. The overall coincidence rate of FISH and I HC test results was 82% (41/50) (K = 0.581). Conclusion: The FISH method has high stability and reliability. To detect the amplification of Her-2 / neu gene by FISH in clinical practice as a supplement to I HC method can be more accurate and objective for the treatment and prognosis of patients with breast cancer Evaluation.